Imagion Biosystems Limited (ASX:IBX)

Market Cap	3.02M
Revenue (ttm)	2.67M
Net Income (ttm)	-2.07M
Shares Out	201.34M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,500
Average Volume	13,115,172
Open	0.0160
Previous Close	0.0150
Day's Range	0.0150 - 0.0160
52-Week Range	0.0110 - 0.0800
Beta	1.43
RSI	50.49
Earnings Date	Aug 28, 2025

About Accolade

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IBX

Financial Performance

In 2024, Imagion Biosystems's revenue was 2.67 million, a decrease of -46.38% compared to the previous year's 4.97 million. Losses were -2.07 million, -83.43% less than in 2023.